Spruce Biosciences’ stock plummets in wake of PhIIb flop, biotech to cut staff
14 Mar 2024
Phase 2Clinical ResultClinical Trial Failure
Spruce Biosciences’ tildacerfont failed a Phase IIb test in adults with congenital adrenal hyperplasia (CAH) due to compliance issues, crushing its stock $SPRB by as much as 75% premarket.
In the 96-patient CAHmelia-203 trial, the oral CRF1 receptor antagonist did not meet the primary endpoint of change in androstenedione (A4) levels at 12 weeks. The company said there was low compliance with the drug and standard of care glucocorticoid (GC) steroids, with only about half of patients noting they were at least 80% compliant.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.